Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2022-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to compare the medication adherence measured by PDC of patients with FDC or double-pill combination therapy in real-world Japanese therapeutic practice.The further objective of this study is how much influence the background of patients to the adherence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

NCT01911780

Hypertension

COMPLETED PHASE3

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

NCT02183675

Healthy

COMPLETED PHASE1

Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine

NCT00509470

Essential Hypertension

COMPLETED PHASE4

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

NCT01286558

Hypertension

COMPLETED PHASE3

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

NCT02738632

Essential Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telmisartan and hydrochlorothiazide group

subjects treated with telmisartan/hydrochlorothiazide

Intervention Type DRUG

subjects treated with telmisartan/hydrochlorothiazide

Telmisartan and amlodipine group

Subjects treated with Telmisartan and amlodipine

Intervention Type DRUG

Subjects treated with Telmisartan and amlodipine

Telmisartan+hydrochlorothiazide double-pill combination group

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

Intervention Type DRUG

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

telmisartan+amlodipine double-pill combination group

subjects treated with telmisartan+amlodipine double pill

Intervention Type DRUG

subjects treated with telmisartan+amlodipine double pill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

subjects treated with telmisartan/hydrochlorothiazide

Intervention Type DRUG

Subjects treated with Telmisartan and amlodipine

Intervention Type DRUG

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

Intervention Type DRUG

subjects treated with telmisartan+amlodipine double pill

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MICARDIS, PRITOR, TELMISARTAN MICARDIS, PRITOR, TELMISARTAN MICARDIS, PRITOR, TELMISARTAN MICARDIS, PRITOR, TELMISARTAN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with hypertension
* Patients must have their first prescription (defined as index date\*) for telmisartan and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010
* Patients must have their first prescription (defined as index date\*) for telmisartan and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011
* Patients must have at least 180 days follow up verified by the presence of prescription record

Exclusion Criteria

* Patients who were under 40 years old at the time of enrolment
* Patients who prescribed the study drugs less than 90 days during a follow up period of 180 days
* Patients whose visits are less than 2 times during a follow up period of 180 days

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No